Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Optimal Cellular Prediction (OCP)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Condensed matter physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Netherlands
Call: ERC Advanced Grant (ERC-2019-ADG, 2019)
Start date: 2021-04-01
End date: 2026-09-30
Duration (months): 66.0
Total project cost (EUR): 2496750.0
EU funding (EUR): 2496750.0
Participants: 1
Project status: SIGNED

The ability to respond to changes in the environment is a defining property of life. Strikingly, experiments have vividly demonstrated that even single-celled organisms can leverage correlations in the environmental fluctuations to predict the future environment and mount a response ahead of time. Yet, how reliably single cells can do so and what the fitness benefit of prediction is, are wide-open questions. To predict the future environment, cells need to compress the past signal into the dynamics of the intracellular biochemical network from which the future input is inferred. Yet, storing information is costly while not all features of the past signal are equally informative on the future input signal. Using measures from information theory and ideas from statistical physics, we will study network motifs and environmental stimuli of increasing complexity to derive the fundamental limit to the prediction accuracy as set by the information on the past. We will determine how close biochemical networks can come to this bound, and how this depends on the topology of the network and the resources to build and operate it – protein copies, time, and energy. We will elucidate how the features of the past signal that are most informative about the future signal are encoded in these optimal networks, and how the cell decodes these. The studies on these minimal model systems will uncover general principles of cellular prediction. We will use our theoretical framework to set up experiments that allow us to test whether two specific biological systems – the E. coli chemotaxis system and the glucose sensing system of yeast – have implemented the uncovered design principles for optimal cellular prediction. We will measure how close these systems come to the fundamental bound on the prediction precision and how this constrains their fitness. We envision that this program will establish information transmission efficiency as a paradigm for understanding cellular function.

Keywords: information theory,stochastic thermodynamics,biochemical networks,cell signalling
Solutions for TCO optimized electrification of city bus systems (ELINKKER)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Finland
Call: Small business innovation research for Transport (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-03-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Linkker has developed total cost of ownership (TCO) optimized concept for electrification of city bus systems. Linkker solutions are lightweight city bus, energy efficient battery electric vehicle systems (BEV system) and conversion kits for bus retrofits. Objective of 1st phase of commercialization is to study commercial potential of energy efficient bus system developed by Linkker in European cities. Speed up roll-out of energy efficient electric bus systems in a few selected cities in Europe for reduced emissions and lower TCO (Total Cost of Ownership). Faster transition will help cities achieve cost savings for public transportation quicker, reduce emissions faster and finally accelerate electric bus activities by European industry. This is our focus in Phase 1. Long term objective is together with cities and bus operators to increase attractiveness of public transport with sustainable electric buses, which offer superior user experience.

Keywords: tco optimized,electrified bus system,no local emissions,energy efficient power train,opportunity charging,lightweight construction,improved attractiveness of public transportation
SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068 (VSV-EBOPLUS)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Italy,Switzerland,Sweden,Switzerland,Netherlands,United States,Brazil,Gabon
Call: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks (H2020-JTI-IMI2-2015-08-single-stage, 2015)
Start date: 2016-04-01
End date: 2023-03-31
Duration (months): 84.0
Total project cost (EUR): 15430660.0
EU funding (EUR): 8553750.0
Participants: 11
Project status: SIGNED

The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine “take”, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US). Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children. We propose: 1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOV;

Keywords: ebola,ebola vaccine,clinical trials,system vaccinology,transcriptomics,immunogenicity,signatures
Illuminating GENome Organization through integrated MIcroscopy and Sequencing (GENOMIS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Sweden
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2018-01-01
End date: 2023-12-31
Duration (months): 72.0
Total project cost (EUR): 1499808.0
EU funding (EUR): 1499808.0
Participants: 1
Project status: SIGNED

In human cells, two meters of DNA sequence are compressed into a nucleus whose linear size is five orders of magnitude smaller. Deciphering how this amazing structural organization is achieved and how DNA functions can ensue in the environment of a cell’s nucleus represent central questions for contemporary biology. Here, I embrace this challenge by establishing a comprehensive framework of microscopy and sequencing technologies coupled with advanced analytical approaches, aimed at addressing three fundamental highly-interconnected questions: 1) What are the design principles that govern DNA compaction? 2) How does genome structure vary between different cell types as well as among cells of the same type? 3) What is the link between genome structure and function? In preliminary experiments, we have devised a powerful method for Genomic loci Positioning by Sequencing (GPSeq) in fixed cells with optimally preserved nuclear morphology. In parallel, we are developing high-end microscopy tools for simultaneous localization of dozens of genomic locations at high resolution in thousands of single cells. We will obtain first-ever genome-wide maps of radial positioning of DNA loci in the nucleus, and combine them with available DNA contact probability maps in order to build 3D models of the human genome structure in different cell types. Using microscopy, we will visualize chromosomal shapes at unprecedented resolution, and use these rich datasets to discover general DNA folding principles. Finally, by combining high-resolution chromosome visualization with gene expression profiling in single cells, we will explore the link between DNA structure and function. Our study shall illuminate the design principles that dictate how genetic information is packed and read in the human nucleus, while providing a comprehensive repertoire of tools for studying genome organization.

Keywords: genome organization,chromosomes,gene expression,fluorescence in situ hybridization,next generation sequencing,single molecule studies
Towards the Understanding a Metal-Tumour-Metabolism (ToMeTuM)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Czechia
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-01-01
End date: 2023-02-28
Duration (months): 62.0
Total project cost (EUR): 1377495.0
EU funding (EUR): 1377495.0
Participants: 1
Project status: CLOSED

A tumour cell uses both genetic and protein weapons in its development. Gaining a greater understanding of these lethal mechanisms is a key step towards developing novel and more effective treatments. Because the metal ion metabolism of a tumour cell is not fully understood, we will address the challenge of explaining the mechanisms of how a tumour cell copes both with essential metal ions and platinum based drugs. The metal-based mechanisms help a tumour to grow on one side and to protect itself against commonly used metal-based drugs. On the other side, the exact description of these mechanisms, which are being associated with multi-drug resistance occurrence and failure of a treatment, still remains unclear. We will reveal the mechanism of the as yet not understood biochemical and molecularly-biological relationships and correlations between metal ions and proteins in a tumour development revealing the way how to suppress the growth and development of a tumour and to markedly enhance the effectiveness of a treatment. To achieve this goal, we will focus on metallothionein and its interactions with essential metals and metal-containing anticancer drugs (cisplatin, carboplatin, and oxaliplatin). Their actions will be monitored both in vitro and in vivo. For this purpose, we will optimize electrochemical, mass spectrometric and immune-based methods. Based on processing of data obtained, new carcinogenetic pathways will be sought on cell level and proved by genetic modifications of target genes. The discovered processes and the pathways found will then be tested on two animal experimental models mice bearing breast tumours (MCF-7 and 4T1) and MeLiM minipigs bearing melanomas. The precise description of the tumour related pathways coping with metal ions based on metallothioneins will direct new highly effective treatment strategies. Moreover, the discovery of new carcinogenetic pathways will open a window for understanding of cancer formation and development.

Keywords: metallothionein,zinc,copper,tumour,treatment,platinum cytostatics,cells,animal,genetic modification,crispr,mirna,protein oligomerization,electrochemistry,spectrometry,immunochemistry
Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents (AptaCheck)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Denmark
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-2-2016-2017, 2017)
Start date: 2017-08-01
End date: 2019-07-31
Duration (months): 24.0
Total project cost (EUR): 2254187.5
EU funding (EUR): 1577931.0
Participants: 1
Project status: CLOSED

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

Keywords: lab on a chip,impedance biosensor,electrical impedance spectroscopy,aptamers,conductive,polymer electrodes,virus,infection,advanced manufacturing
high-EfficienT piEzoelectRic vibratioN energy hArvester for raiL track system (ETERNAL)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 337400.64
EU funding (EUR): 337400.64
Participants: 1
Project status: SIGNED

Railway track and rolling stock interact with each other, forming a complex dynamic system which leads to structural degradation of railway assets with time, as such, pose a threat to not only safety, but comfortable rail operations. Modern ICT and sensing technologies could ensure a safe, secure and efficient transport network. However, greater connectivity and sensor coverage along tracks which require no mains power or batteries for energy supply, eliminating the costs for cabling and battery replacement, and minimum gateway installations, are critical for the success of industry adoptions. As such, the ETERNAL fellowship is providing a solution towards to the development of self-powered Internet-of-Things (IoT) devices for railway system by harvesting the vibration energy when the train travels. Through new, insightful laboratory investigations supported by numerical simulations, a vibration-based piezoelectric energy harvesting prototype is developed for the railway system. ETERNAL establishes inner links between the excitation source and the component natural frequency in rail track systems, and develops the piezoelectric ceramics by combining texturing process and multilayered structure together, which take the functionality (large output current, high energy density, low cost, and high mechanical strength) of the piezoelectric vibration energy harvester (PVEH) to the next level. This fellowship advances the underpinning technology for developing an energy harvester with the ultimate goal of developing self-powered IoT devices, which expected to transform rail track monitoring capability and ensure a more sustainable railway development in the 21st century, in the EU and internationally.

Keywords: piezoelectric ceramics,energy harvester,train mechanical vibration
Mobility for Regional Excellence 2020 (MoRE2020)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes (COFUND)-Fellowship programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Sweden,Sweden
Call: Co-funding of regional, national and international programmes (H2020-MSCA-COFUND-2016, 2016)
Start date: 2017-05-01
End date: 2022-04-30
Duration (months): 60.0
Total project cost (EUR): 1416000.0
EU funding (EUR): 708000.0
Participants: 7
Project status: CLOSED

MoRE2020 is a continuation and further development of the FP7-Marie Curie-COFUND programme called “Mobility for Regional Excellence” (MoRE), which Region Västra Götaland was granted in December 2013 (grant agreement no 608743). The half-term external evaluation of the MoRE programme indicated very positive results. MoRE2020 will offer experienced researchers new and exciting mobility experiences in internationally renowned research and innovation milieus with excellent working conditions and strong triple helix components. It aims to contribute to increasing the attractiveness of research and innovation careers in Europe, to foster excellence across the Union through smart specialisation, and to increase international cooperation. MoRE2020 is a moderately scaled programme – a total of 20 incoming/outgoing fellows will be supported throughout the programme period. Being a small programme, it will compete on quality rather than on quantity. Key features of the MoRE2020 programme: • The programme covers incoming and outgoing mobility • There are no geographical restrictions regarding host research and innovation milieus abroad • The programme will be open to experienced researchers of all nationalities • The fellowships will be awarded for 12 months during a 24 months period • The applicant is an experienced researcher together with a research and innovation milieu in Västra Götaland • Only employment contracts, no stipends, are allowed • The programme allows research in a broad number of fields connected to smart specialisation areas in Västra Götaland • The applicant milieu in Västra Götaland co-finances approximately 25% of the fellowship, to ensure a strong commitment to the career development of the researcher and to the success of the project • Applications will be evaluated in a transparent international peer-review process

Keywords: researcher,mobility,v stra g taland,research driven clusters,cofund,more,triple helix,smart specialisation,excellence,innovation,regional programme
Non-invasive clinical markers for diagnosis of endometriosis (GLYCOMENDO)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-09-02
End date: 2021-09-01
Duration (months): 24.0
Total project cost (EUR): 196590.72
EU funding (EUR): 196590.72
Participants: 1
Project status: CLOSED

Endometriosis is a chronic disease that affects 10% of all women of reproductive age. It is characterized by the ectopic growth of endometrial tissue outside the uterus and is a major cause of pelvic pain and disability. Endometriosis also has an adverse effect on fertility, with almost one third of patients failing to conceive. The aetiology of endometriosis is unknown and a definitive diagnosis of endometriosis requires invasive laparoscopic surgery, and treatment options are limited in number and efficacy. This research proposal will adopt an integrated, systems biology approach to finely characterize how circulating and local uterine glycoprotein profiles are altered in endometriosis, and how such profiles may be influenced by dysbiosis of the uterine microbial ecosystem including possible intracellular pathogen infection. Using our combined multidisciplinary expertise in glycomics, microbiome and gynaecology, we will use findings from this study to define how changes in glycosylation pattern and microbial profile that are associated with endometriosis may be developed as novel, non-invasive diagnostic markers for the disease. It may also provide insight into disease pathogenesis. Accurate diagnosis and effective treatment of endometriosis has the potential to significantly reduce the healthcare cost burden associated with current strategies and may increase success rates of pregnancy and live births in these patients. This collaborative translational research project will be primarily based at NIBRT (SME, host institution), with secondments in APC Microbiome Institute, University College Cork (UCC), and also at the Merrion Fertility Clinic (MFC) and University College Dublin Centre for Support and Training in Analysis and Research (UCD CSTAR).

Keywords: gynaecology,infertility,endometriosis,microbiology,glycobiology,glucose metabolism,serum,uplc,mass spectrometry,quantitative pcr,clinical marker,biomarker,multidisciplinary